SBRA · REIT · FFO, book-value and yield view
Sabra Health Care REIT, Inc. (SBRA): Valuation Snapshot
Sabra Health Care REIT, Inc. (SBRA) is a real-estate investment trust, and a discounted-cash-flow model is the wrong lens for one, so TickerWorth does not publish a DCF fair value for it. What its filings and market data do show is below. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
How is a REIT like SBRA valued?
This is a REIT. A free-cash-flow DCF is structurally the wrong lens for property: heavy depreciation and continuous property capex swamp reported free cash flow, which is why REITs are valued on FFO/AFFO, net asset value and dividend yield. We show those lenses instead of a DCF number we would not stand behind.
What is SBRA's TickerWorth Score?
Middle of the pack — real strengths and real weaknesses
Compared with Real Estate companies in US
Its strongest point: growing quickly. Its weakest: profitability is weak.
- Value · 41 of 100
Cheaper than 41% of Real Estate companies in US
- Price vs worth · — of 100
- Quality · 14 of 100
More profitable than 14% of Real Estate companies in US
- Financial health · 60 of 100
Financially stronger than 60% of Real Estate companies in US
- Growth · 96 of 100
Growing faster than 96% of Real Estate companies in US
- Momentum · 58 of 100
Outperformed 58% of Real Estate companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $19.17
- Market cap
- $4,
897, 221, 120 - 52-week high
- $22.77
- 52-week low
- $17.17
- Currency
- USD
- Exchange
- NasdaqGS
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
Sabra Health Care REIT, Inc. (SBRA) is a real-estate investment trust, and a free-cash-flow discounted-cash-flow (DCF) model is structurally the wrong lens for one. A REIT's reported free cash flow is swamped by property depreciation and the continuous capital spending that maintaining a portfolio requires, which is why the industry is valued on funds from operations (FFO/AFFO), net asset value and dividend yield instead. We have the data to print a DCF number for SBRA; we don't publish one because it would not mean what it appears to mean. What follows is how a REIT is actually read — descriptive, not a valuation, and not investment advice.
Read the full reasoning
On the numbers we do have, SBRA trades at a recent price of $19.17, a market capitalisation of about $4,897,221,120, sitting 36% of the way up its 52-week range ($17.17–$22.77), on the NasdaqGS.
The standard alternative to a DCF is relative valuation — comparing SBRA's trading multiples against a sector benchmark. Here that gives P/E of 76.7× (richer than the peer median of 27.7×); Fwd P/E of 23.7× (cheaper than the peer median of 36.1×); P/B of 1.8× (cheaper than the peer median of 6.8×); P/S of 5.7× (cheaper than the peer median of 9.8×); EV/EBITDA of 19.9× (in line with the peer median of 19.3×); Dividend yield of 6.3% (cheaper than the peer median of 3.9%). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. SBRA shows a price-to-book (P/B) of 1.78 and book value of $10.77 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. SBRA is in a mixed trend, trading -15.8% from its 52-week high. Over the past year the stock is +4.9%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
To be exact about what this page is not: we are not saying the numbers for SBRA are unavailable. They are, and they are above. We are saying a discounted-cash-flow model is the wrong instrument for this kind of business, and publishing one anyway — because the inputs happen to exist — would be a precise answer to the wrong question. Refusing is the more useful answer, and it is the same rule we apply to every name in this category.
SBRA vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | SBRA | Peer median | Read |
|---|---|---|---|
| P/E | 76.7× | 27.7× | richer than |
| Fwd P/E | 23.7× | 36.1× | cheaper than |
| P/B | 1.8× | 6.8× | cheaper than |
| P/S | 5.7× | 9.8× | cheaper than |
| EV/EBITDA | 19.9× | 19.3× | in line with |
| Dividend yield | 6.3% | 3.9% | cheaper than |
What does Sabra Health Care REIT, Inc. do?
What does it do?
Sabra Health Care REIT, Inc. operates as a self-administered, self-managed real estate investment trust that, through its subsidiaries, owns and invests in real estate serving the healthcare industry throughout the United States and Canada. It operates in the REIT - Healthcare Facilities industry (Real Estate sector), headquartered in United States. The company employs roughly 58 people.
How does it make money?
The business turns $864M in annual revenue into profit. Out of every $100 of sales, about $0 is left as operating profit (operating margin of -12.5%), after a 50% gross margin on the products/services it sells. After all costs, taxes and interest, 7.6% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: carries modest debt (1.0× equity), comfortably covers its short-term bills (3.6× current ratio), and is currently profitable.
Who at SBRA filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Kono Ann | Director | Grant / award | — | Form 4 for Kono Ann (opens sec.gov in a new tab) | |
| KATZMANN LYNNE S | Director | Grant / award | — | Form 4 for KATZMANN LYNNE S (opens sec.gov in a new tab) | |
| FOSTER MICHAEL J | Director | Grant / award | — | Form 4 for FOSTER MICHAEL J (opens sec.gov in a new tab) | |
| Cusack Catherine | Director | Grant / award | — | Form 4 for Cusack Catherine (opens sec.gov in a new tab) | |
| Barbarosh Craig A. | Director | Grant / award | — | Form 4 for Barbarosh Craig A. (opens sec.gov in a new tab) | |
| FLORES JESSICA | Executive VP & CAO | Grant / award | — | Form 4 for FLORES JESSICA (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.